Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2003 1
2004 7
2005 13
2006 15
2007 9
2008 11
2009 3
2010 2
2011 2
2012 1
2013 1
2014 3
2015 2
2016 1
2017 3
2018 4
2019 3
2020 5
2021 9
2022 5
2023 4
2024 7
2025 8
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

108 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Attal M, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Chiu C, Wang J, Van Rampelbergh R, Uhlar CM, Kobos R, Qi M, Usmani SZ; MAIA Trial Investigators. Facon T, et al. N Engl J Med. 2019 May 30;380(22):2104-2115. doi: 10.1056/NEJMoa1817249. N Engl J Med. 2019. PMID: 31141632 Free PMC article. Clinical Trial.
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M; OPTIMISMM trial investigators. Richardson PG, et al. Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13. Lancet Oncol. 2019. PMID: 31097405 Clinical Trial.
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
Kiladjian JJ, Marin FF, Al-Ali HK, Alvarez-Larrán A, Beggiato E, Bieniaszewska M, Breccia M, Buxhofer-Ausch V, Cerna O, Crisan AM, Danaila CD, De Stefano V, Döhner K, Empson V, Gora-Tybor J, Griesshammer M, Grosicki S, Guglielmelli P, García-Gutierrez V, Heidel FH, Illés A, Tomuleasa C, James C, Koschmieder S, Krauth MT, Krejcy K, Lazaroiu MC, Mayer J, Nagy ZG, Nicolini FE, Palandri F, Pappa V, Reiter AJ, Sacha T, Schlager S, Schmidt S, Terpos E, Unger M, Wölfler A, Cirici BX, Klade C. Kiladjian JJ, et al. Ann Hematol. 2024 Jul;103(7):2299-2310. doi: 10.1007/s00277-024-05665-4. Epub 2024 Mar 4. Ann Hematol. 2024. PMID: 38438627 Free PMC article.
Phenotypic characterization of disease-initiating stem cells in JAK2- or CALR-mutated myeloproliferative neoplasms.
Ivanov D, Milosevic Feenstra JD, Sadovnik I, Herrmann H, Peter B, Willmann M, Greiner G, Slavnitsch K, Hadzijusufovic E, Rülicke T, Dahlhoff M, Hoermann G, Machherndl-Spandl S, Eisenwort G, Fillitz M, Sliwa T, Krauth MT, Bettelheim P, Sperr WR, Koller E, Pfeilstöcker M, Gisslinger H, Keil F, Kralovics R, Valent P. Ivanov D, et al. Am J Hematol. 2023 May;98(5):770-783. doi: 10.1002/ajh.26889. Epub 2023 Mar 9. Am J Hematol. 2023. PMID: 36814396 Free PMC article.
Pathway-Directed Therapy in Multiple Myeloma.
John L, Krauth MT, Podar K, Raab MS. John L, et al. Cancers (Basel). 2021 Apr 1;13(7):1668. doi: 10.3390/cancers13071668. Cancers (Basel). 2021. PMID: 33916289 Free PMC article. Review.
European Expert Panel Consensus on Outpatient Administration of Teclistamab and Talquetamab in Patients With Multiple Myeloma: Feasibility, Key Considerations, and Future Directions.
Lund T, Khandanpour C, Anguille S, Kisro J, Krauth MT, Lund J, Nijhof I, Ocio EM, Zamagni E, Javelot M, Albrecht C, Cerezo CE, Perrot A. Lund T, et al. Eur J Haematol. 2025 Oct;115(4):358-366. doi: 10.1111/ejh.14444. Epub 2025 Jun 26. Eur J Haematol. 2025. PMID: 40571970 Free PMC article.
Non-Invasive Stratification of Portal Hypertension in Patients With BCR::ABL1-Negative Myeloproliferative Neoplasms.
Balcar L, Degenfeld-Schonburg L, Hopp C, Kramer G, Graf I, Simonis L, Sillaber C, Kalteis S, Gisslinger H, Meischl T, Stättermayer AF, Mandorfer M, Mitterbauer-Hohendanner G, Reiberger T, Trauner M, Scheiner B, Krauth MT, Semmler G. Balcar L, et al. Liver Int. 2025 Jun;45(6):e70098. doi: 10.1111/liv.70098. Liver Int. 2025. PMID: 40332039 Free PMC article.
[Venous thromboembolism].
Krauth MT, Pabinger I. Krauth MT, et al. Wien Klin Wochenschr. 2007;119(5-6 Suppl 1):11-8; quiz 19. doi: 10.1007/s11812-006-0019-0. Wien Klin Wochenschr. 2007. PMID: 17939278 Review. German. No abstract available.
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
Schjesvold FH, Dimopoulos MA, Delimpasi S, Robak P, Coriu D, Legiec W, Pour L, Špička I, Masszi T, Doronin V, Minarik J, Salogub G, Alekseeva Y, Lazzaro A, Maisnar V, Mikala G, Rosiñol L, Liberati AM, Symeonidis A, Moody V, Thuresson M, Byrne C, Harmenberg J, Bakker NA, Hájek R, Mateos MV, Richardson PG, Sonneveld P; OCEAN (OP-103) Investigators. Schjesvold FH, et al. Lancet Haematol. 2022 Feb;9(2):e98-e110. doi: 10.1016/S2352-3026(21)00381-1. Epub 2022 Jan 12. Lancet Haematol. 2022. PMID: 35032434 Clinical Trial.
Paraneoplastic autoimmune thrombocytopenia in solid tumors.
Krauth MT, Puthenparambil J, Lechner K. Krauth MT, et al. Crit Rev Oncol Hematol. 2012 Jan;81(1):75-81. doi: 10.1016/j.critrevonc.2011.02.004. Epub 2011 Apr 22. Crit Rev Oncol Hematol. 2012. PMID: 21515071 Review.
108 results